Oramed Pharmaceuticals Files 8-K on Material Agreement
Ticker: ORMP · Form: 8-K · Filed: Nov 17, 2025 · CIK: 1176309
| Field | Detail |
|---|---|
| Company | Oramed Pharmaceuticals Inc. (ORMP) |
| Form Type | 8-K |
| Filed Date | Nov 17, 2025 |
| Risk Level | medium |
| Pages | 7 |
| Reading Time | 8 min |
| Key Dollar Amounts | $0.012, $10.00 |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, 8-k, filing
TL;DR
Oramed just filed an 8-K for a new material agreement - big news incoming.
AI Summary
Oramed Pharmaceuticals Inc. filed an 8-K on November 17, 2025, reporting on a material definitive agreement entered into on November 16, 2025. The filing also covers material modifications to the rights of security holders and includes financial statements and exhibits. The company is incorporated in Delaware and its principal executive offices are located at 1185 Avenue of the Americas, New York.
Why It Matters
This 8-K filing indicates a significant new agreement for Oramed Pharmaceuticals, which could impact its business operations, financial standing, and future strategic direction.
Risk Assessment
Risk Level: medium — Material definitive agreements can introduce new risks or opportunities that are not yet fully understood by the market.
Key Players & Entities
- Oramed Pharmaceuticals Inc. (company) — Registrant
- November 16, 2025 (date) — Date of earliest event reported
- November 17, 2025 (date) — Date of report
- 1185 Avenue of the Americas, Third Floor, New York (location) — Business address
FAQ
What is the nature of the material definitive agreement entered into by Oramed Pharmaceuticals?
The filing does not specify the details of the material definitive agreement, only that one was entered into on November 16, 2025.
What are the key items reported in this 8-K filing?
This 8-K reports on the entry into a material definitive agreement, material modifications to the rights of security holders, and includes financial statements and exhibits.
When was the report filed and what is the earliest event date?
The report was filed on November 17, 2025, and the earliest event reported is November 16, 2025.
Where is Oramed Pharmaceuticals Inc. headquartered?
Oramed Pharmaceuticals Inc.'s business address is 1185 Avenue of the Americas, Third Floor, New York.
What is Oramed Pharmaceuticals Inc.'s fiscal year end?
Oramed Pharmaceuticals Inc.'s fiscal year ends on December 31.
Filing Stats: 1,977 words · 8 min read · ~7 pages · Grade level 15.2 · Accepted 2025-11-17 08:50:42
Key Financial Figures
- $0.012 — ch registered Common Stock, par value $0.012 ORMP The Nasdaq Capital Market, Te
- $10.00 — one share of Common Stock at a price of $10.00 per share of Common Stock (the "Purchas
Filing Documents
- ea0265959-8k_oramed.htm (8-K) — 38KB
- ea026595901ex4-1_oramed.htm (EX-4.1) — 238KB
- ea026595901ex99-1_oramed.htm (EX-99.1) — 9KB
- 0001213900-25-111298.txt ( ) — 503KB
- ormp-20251116.xsd (EX-101.SCH) — 3KB
- ormp-20251116_lab.xml (EX-101.LAB) — 33KB
- ormp-20251116_pre.xml (EX-101.PRE) — 22KB
- ea0265959-8k_oramed_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ORAMED PHARMACEUTICALS INC. Date: November 17, 2025 By: /s/ Nadav Kidron Name: Nadav Kidron Title: President and Chief Executive Officer 4